Technology Information Law Blog by Charles Gideon Korrell

Tag: obviousness

  • Federal Circuit Reverses Invalidity Finding for Novartis’ Entresto Patent

    On January 10, 2025, the Federal Circuit issued a significant decision in In re Entresto (Sacubitril/Valsartan) Patent Litigation, reversing a district court ruling that had found claims of Novartis’ U.S. Patent 8,101,659 (“the ’659 patent”) invalid for lack of written description. The appellate court affirmed the district court’s rulings that the patent was not invalid for obviousness or lack of enablement, solidifying Novartis’ ability to protect its blockbuster drug, Entresto®.

    This decision highlights several key patent law principles, particularly in the areas of written description, enablement, and obviousness. Here’s a breakdown of the major issues addressed by the court.

    1. Written Description – The Core Issue on Appeal

    The Federal Circuit reversed the district court’s finding that the ’659 patent lacked an adequate written description. The lower court had ruled that because the patent did not describe a valsartan-sacubitril complex, it failed the written description requirement. However, the Federal Circuit clarified that the claims did not specifically require such a complex—they covered valsartan and sacubitril administered in combination, not in a bound form.

    Key Takeaway:

    A patent’s written description must support what is actually claimed, not an unclaimed feature of the accused product. The court found that the patent sufficiently described the claimed combination therapy, even though it did not describe the later-developed valsartan-sacubitril complex.

    2. Enablement – The Patent Need Only Enable the Claimed Invention

    The district court had found that the ’659 patent enabled the claimed invention, and the Federal Circuit affirmed this conclusion. The court held that because valsartan-sacubitril complexes were unknown at the time of filing, Novartis was not required to enable them in its patent.

    Key Takeaway:

    Later-developed technologies cannot be used to argue that an earlier patent lacks enablement. If the claimed invention was enabled based on the state of the art at the time of filing, the patent remains valid.

    3. Obviousness – No Clear Motivation to Combine

    The court also upheld the district court’s ruling that the asserted claims were not obvious. The defendants (generic pharmaceutical manufacturers) argued that a person of ordinary skill in the art would have been motivated to combine an ARB (valsartan) and an NEP inhibitor (sacubitril) based on prior studies of similar drug combinations.

    However, the court found:

    • The prior art did not directly suggest combining valsartan with sacubitril.
    • Sacubitril was one of over 100 known NEP inhibitors in 2002, and it had never been tested in humans or animals for hypertension or heart failure.
    • The available studies on other NEP inhibitors showed discouraging results.

    Key Takeaway:

    Obviousness cannot be based on hindsight—just because an invention later proves effective does not mean it was obvious at the time of the patent filing.

    Conclusion: A Win for Novartis and Strong Patent Protection

    This decision strengthens Novartis’ patent protection for Entresto®, a drug with annual U.S. sales exceeding $3 billion. It reinforces the principle that:

    1. The written description requirement applies to what is actually claimed, not later-developed variants of the product.
    2. Enablement is judged based on what was known at the time of filing, not what was developed later.
    3. Obviousness must be based on clear motivation and reasonable expectation of success from the prior art.

    For pharmaceutical innovators, this case underscores the importance of careful patent drafting and robust litigation strategies. Meanwhile, for generic manufacturers, it highlights the challenges of proving invalidity when prior art does not clearly suggest the patented invention.

    By Charles Gideon Korrell

  • Federal Circuit Overturns PTAB Decision in Honeywell v. 3G Licensing: A Victory for Obviousness Challenges

    On January 2, 2025, the Federal Circuit issued a significant ruling in Honeywell International Inc. v. 3G Licensing, S.A., reversing the Patent Trial and Appeal Board’s (PTAB) decision that upheld the validity of U.S. Patent No. 7,319,718. This ruling underscores the court’s approach to obviousness under 35 U.S.C. § 103 and highlights critical considerations in intellectual property disputes, particularly in standard-essential patents.

    Background: The ‘718 Patent and the CQI Coding Method

    The case centered around the ‘718 patent, which covers a method for encoding Channel Quality Indicator (CQI) data in third-generation (3G) mobile communication systems. CQI is used by mobile devices to inform base stations about network conditions, helping optimize data transmission rates.

    Honeywell and other appellants challenged the ‘718 patent in an inter partes review (IPR), arguing that the claimed method was obvious in light of prior art, particularly a proposal from Koninklijke Philips N.V. (the Philips reference). The PTAB, however, found that Honeywell failed to demonstrate a motivation to modify the Philips reference in the specific way claimed by the ‘718 patent.

    The Federal Circuit’s Analysis: Legal Issues in Patent Obviousness

    The Federal Circuit reversed the PTAB, concluding that its findings were legally flawed and unsupported by substantial evidence. The ruling focused on four major issues of patent law:

    1. Motivation to Modify Prior Art: Must It Match the Patentee’s Objective?

    The PTAB had determined that because the ‘718 patent aimed to maximize system throughput, there was no motivation for a skilled artisan to modify the Philips reference to enhance protection for the most significant bit (MSB). The Federal Circuit rejected this reasoning, reaffirming that obviousness does not require the motivation to match the patentee’s goal. Citing KSR International Co. v. Teleflex Inc., the court emphasized that any recognized need in the field—not just the inventor’s specific motivation—can support a finding of obviousness.

    2. Prior Art and the Role of Technical Modifications

    The court found that the Philips reference itself taught the desirability of protecting the MSB and that swapping two bits in the encoding table (as the ‘718 patent claimed) was a straightforward optimization. Because the modification merely involved a minor technical adjustment, it fell within the realm of routine experimentation and optimization rather than a novel innovation.

    3. Conflation of Obviousness and Anticipation

    The Federal Circuit criticized the PTAB for improperly treating the lack of an explicit proposal to swap the bits in the Philips reference as evidence of non-obviousness. The court clarified that while anticipation requires every element to be disclosed in a single prior art reference, obviousness merely requires that the claimed modification would have been a natural and logical step for a skilled person.

    4. The “Best Approach” Fallacy in Standards Development

    The PTAB had focused on the lack of consensus within the 3G standards-setting process regarding optimal CQI encoding methods. The Federal Circuit held that obviousness does not require a modification to be the “best” or “preferred” approach, only that it be a reasonable and predictable improvement.

    Implications for Patent Law and Standard-Essential Patents

    This decision reinforces the high bar for patentability in the face of well-documented prior art. Some key takeaways include:

    • Obviousness analysis should not be constrained by the inventor’s specific motivations but should consider broader industry knowledge.
    • Technical refinements and optimizations may not be patentable if they represent routine modifications of existing methods.
    • Standard-setting bodies’ debates do not necessarily shield patents from invalidity challenges—if an approach was reasonably suggested by prior art, it may still be deemed obvious.

    Conclusion

    The Federal Circuit’s decision in Honeywell v. 3G Licensing serves as a reminder that minor tweaks to well-known technologies, even when adopted into industry standards, may not be enough to sustain patent validity. As companies continue to litigate standard-essential patents, courts will likely scrutinize whether claimed inventions represent true innovation or merely expected refinements of prior art.

    This ruling is a win for companies challenging weak patents in high-tech industries and signals a continued shift toward a pragmatic and evidence-driven approach to patent law.

  • Federal Circuit Vacates PTAB Decision in Palo Alto Networks v. Centripetal Networks: Key Patent Law Takeaways

    On December 16, 2024, the Federal Circuit issued an opinion in Palo Alto Networks, Inc. v. Centripetal Networks, LLC, vacating and remanding a decision by the Patent Trial and Appeal Board (PTAB) in an inter partes review (IPR) proceeding. The ruling highlights critical issues in patent law, particularly regarding obviousness, motivation to combine, and the sufficiency of PTAB’s reasoning in IPR decisions.

    Background of the Case

    The dispute concerns U.S. Patent No. 10,530,903 (the ’903 patent), owned by Centripetal Networks, which covers a system for correlating network packets to improve cybersecurity by de-obfuscating packet sources. Palo Alto Networks (PAN) petitioned for IPR, arguing that the claims were obvious over a combination of three prior art references, with the key dispute centering on whether two references—Paxton and Sutton—could be combined to teach a crucial limitation in the patent.

    The PTAB ultimately ruled in favor of Centripetal, finding that PAN had not sufficiently demonstrated the claimed invention was obvious. PAN appealed, arguing that the Board failed to properly analyze the motivation to combine the references.

    Key Patent Law Issues Addressed

    1. Motivation to Combine and the “Necessary Bridge”

    One of the most important legal issues in this case was whether PAN had sufficiently established a motivation to combine the teachings of Paxton (which disclosed packet correlation techniques) and Sutton (which disclosed methods for notifying administrators of potential malicious activity).

    PAN contended that it would have been obvious to modify Paxton’s system by incorporating Sutton’s notification method to improve cybersecurity. The Board, however, concluded that there was no clear “bridge” between the two references that would support a motivation to combine.

    The Federal Circuit found that the Board failed to make a clear finding on the motivation to combine and did not adequately explain what it meant by the “necessary bridge” between Paxton and Sutton. The court emphasized that when an obviousness challenge is raised, the Board must explicitly find whether a motivation exists and provide a clear rationale. Citing In re Nuvasive, Inc., the court reiterated that a Board decision must include specific findings rather than vague assertions that a motivation was not sufficiently demonstrated.

    2. Evaluating Prior Art Combinations as a Whole

    The Federal Circuit also criticized the Board’s piecemeal analysis of the prior art. The PTAB evaluated Paxton and Sutton in isolation rather than considering them together as a combination. The court clarified that the correct test for obviousness is not whether any single reference discloses all claim limitations, but whether a skilled artisan would find it obvious to combine the teachings of multiple references.

    This aligns with the Supreme Court’s ruling in KSR Int’l Co. v. Teleflex Inc., which rejected a rigid approach to obviousness in favor of a more flexible, common-sense inquiry. By failing to consider the prior art references in combination, the PTAB misapplied the law and failed to properly analyze whether the combined references taught the disputed claim limitation.

    3. The Importance of Clear Reasoning in PTAB Decisions

    The Federal Circuit underscored that the PTAB’s reasoning must be sufficiently detailed to allow for meaningful appellate review. While the court does not reweigh evidence, it must ensure that the PTAB’s decisions are supported by substantial evidence and clearly articulated findings.

    The decision in this case reinforces prior holdings, such as in Gechter v. Davidson, which stress that PTAB opinions must be sufficiently reasoned and cannot leave key issues unresolved. The court found that the Board’s failure to explain whether PAN’s arguments about obviousness were valid required a remand.

    Conclusion and Impact on Future Cases

    The Federal Circuit’s decision in Palo Alto Networks v. Centripetal Networks serves as a reminder that PTAB decisions must be clear, specific, and legally sound when analyzing obviousness and motivation to combine. For practitioners handling IPRs, this case highlights the importance of:

    • Providing a well-reasoned explanation for why prior art references should or should not be combined.
    • Ensuring that PTAB panels properly evaluate prior art combinations as a whole rather than in isolation.
    • Holding PTAB accountable for issuing decisions that contain detailed findings and sufficient reasoning to withstand appellate scrutiny.

    As the case is remanded, PTAB will need to reconsider its findings on motivation to combine and whether the combined prior art discloses all claim elements. This ruling could influence future PTAB proceedings by emphasizing the need for thorough and well-supported decisions in IPR disputes.

    By Charles Gideon Korrell

  • Federal Circuit Ruling in Cytiva v. JSR: A Deep Dive into Patent Obviousness and Inherency in Biotechnology

    In a significant decision for biotechnology and pharmaceutical patents, the Federal Circuit has affirmed-in-part and reversed-in-part the Patent Trial and Appeal Board’s (PTAB) findings in Cytiva BioProcess R&D AB v. JSR Corp.. The case centers around chromatography matrices and protein engineering, with the core dispute being whether certain patent claims were obvious and therefore unpatentable. The ruling provides valuable insight into obviousness determinations, inherency doctrine, and the treatment of unexpected results in patent law.

    Background of the Case

    Chromatography is a key technology used to separate and purify biomolecules, particularly in pharmaceutical manufacturing. The patents at issue cover affinity chromatography matrices that use Protein A (SPA) as a ligand to bind antibodies. Cytiva owns three patents related to modified versions of Domain C of SPA, which were designed to improve stability in alkaline environments—a crucial property for reusability in industrial purification processes.

    JSR challenged Cytiva’s patents via six inter partes reviews (IPRs), arguing that the modifications to Domain C were obvious in light of prior art. The PTAB invalidated 79 claims across Cytiva’s patents but upheld four claims that related to binding properties involving the Fab region of an antibody.

    Both companies appealed:

    • Cytiva argued that the Board incorrectly applied the lead compound analysis and that the Fab-binding properties were unexpected.
    • JSR cross-appealed, asserting that the four surviving claims were also inherently obvious.

    Key Patent Law Issues Addressed

    1. Was the “Lead Compound” Analysis Required?

    Cytiva’s core argument was that the PTAB should have applied the lead compound framework, a two-step analysis commonly used in chemical and pharmaceutical patent cases:

    1. Would a skilled artisan have selected Domain C as a starting point?
    2. Would the prior art suggest modifying Domain C with a reasonable expectation of success?

    Court’s Ruling: Lead Compound Analysis Was Unnecessary

    The Federal Circuit rejected Cytiva’s argument, explaining that the lead compound test is not always required—especially when the prior art explicitly suggests a modification. Here, prior research had already identified five homologous domains (A-E) in SPA, and multiple sources explicitly recommended modifying any of them, including Domain C. Because the modification to improve alkaline stability was already known, no additional justification for selecting Domain C was needed.

    Key Takeaway:

    • The lead compound test is not a mandatory hurdle for proving obviousness—courts may bypass it when prior art already suggests the modification.

    2. Was the Modification to Domain C Obvious?

    Cytiva’s patents claimed a G29A mutation, where glycine at position 29 of Domain C was replaced with alanine. This change had already been made to Domain B in prior art and was known to improve alkaline stability.

    Court’s Ruling: The Modification Was Obvious

    The Federal Circuit affirmed the Board’s decision that making the same G29A mutation in Domain C was obvious because:

    • Prior research had explicitly suggested making this mutation to any SPA domain.
    • All five SPA domains share structural and functional similarities.
    • The motivation for the modification was already well-documented.

    Key Takeaway:

    • If a structural change is well-known in related compounds, and the motivation to apply it exists, it is likely obvious.

    3. Did the Board Properly Apply the Inherency Doctrine?

    Several claims covered chromatography matrices that could bind to the Fab region of an antibody. Cytiva argued that this binding property was unexpected and should count as a secondary consideration of nonobviousness.

    Court’s Ruling: The Fab-Binding Property Was Inherent

    The Federal Circuit sided with JSR, ruling that binding to the Fab part of an antibody was an inherent property of the modified SPA ligands. Since the prior art already disclosed SPA binding to antibodies, the presence of Fab binding was merely a natural consequence—not an inventive step.

    The Court reiterated its precedent from Hospira v. Fresenius Kabi (2020), stating:

    “If a property of a composition is inherent, there is no question of a reasonable expectation of success in achieving it.”

    Thus, the claims that survived at the PTAB were reversed and invalidated.

    Key Takeaway:

    • An inherent property of an otherwise obvious modification does not make an invention patentable, even if that property was unexpected.

    4. Does an Unexpected Result Make an Invention Nonobvious?

    Cytiva argued that unexpected Fab-binding properties should overcome the prima facie case of obviousness.

    Court’s Ruling: Unexpected Results Do Not Overcome Inherency

    While unexpected results can support nonobviousness, the Federal Circuit clarified that this applies only when the unexpected result itself is not inherent. In this case:

    • The SPA ligand naturally binds antibodies.
    • Since Fab-binding was an inherent characteristic, it could not be used to prove nonobviousness.

    The Court distinguished this case from Honeywell v. Mexichem (2017), where an unexpected chemical stability rendered a composition nonobvious. Here, binding to the Fab region was inevitable, making any unexpected results irrelevant.

    Key Takeaway:

    • Unexpected results do not override inherency—they must stem from truly novel aspects of an invention.

    Final Outcome and Impact

    IssueFederal Circuit Decision
    Lead compound analysisNot required when prior art suggests modification
    G29A mutation (Domain C)Obvious because it was recommended in prior research
    Fab-binding propertiesInherent—does not support patentability
    Unexpected resultsCannot override inherency—binding was inevitable

    The Federal Circuit affirmed the invalidation of 79 claims and reversed the PTAB’s decision on four remaining claims, declaring all challenged claims unpatentable.

    Why This Case Matters

    1. Sets Limits on the Lead Compound Analysis
      • If prior art already suggests a modification, courts can skip the lead compound test.
    2. Reinforces the Role of Inherency in Patent Law
      • If an invention inevitably exhibits a property, that property cannot make it nonobvious.
    3. Clarifies When Unexpected Results Matter
      • Unexpected properties must not be inherent to impact nonobviousness.

    For biotechnology and pharmaceutical patent holders, this ruling narrows the path for defending patents based on functional properties or unexpected results. If a claimed invention only refines known modifications, it may face heightened obviousness scrutiny.

    By Charles Gideon Korrell

  • Osseo Imaging v. Planmeca: Rejection of Temporal Limitation on Expert Qualifications

    Osseo Imaging v. Planmeca: Rejection of Temporal Limitation on Expert Qualifications

    In its September 2024 decision in Osseo Imaging, LLC v. Planmeca USA Inc., the Federal Circuit reaffirmed the standard for expert qualifications in patent cases, declining to impose a temporal requirement that an expert possess ordinary skill in the art as of the time of invention. The ruling has notable implications for litigation strategy, particularly concerning expert testimony on infringement and validity.

    Background

    Osseo Imaging accused Planmeca of infringing three patents—U.S. Patent Nos. 6,381,301, 6,944,262, and 8,498,374—related to orthopedic imaging systems that create densitometric and tomographic models. Following a jury trial, the District of Delaware entered judgment upholding the jury’s findings of infringement and nonobviousness. On appeal, Planmeca challenged the sufficiency of the evidence, centering its arguments on the qualifications of Osseo’s expert, Dr. Omid Kia.

    Key Issue: Timing of Expert’s Qualification as POSITA

    Planmeca argued that Dr. Kia could not offer substantial evidence on infringement or validity because he did not possess the requisite level of skill in diagnostic imaging in 1999, the patents’ alleged priority date. The Federal Circuit, however, rejected this argument, emphasizing that the governing standard—set forth in Kyocera Senco Indus. Tools Inc. v. ITC, 22 F.4th 1369 (Fed. Cir. 2022)—requires only that an expert possess the ordinary level of skill in the art, not that such skill must have been attained by the date of invention.

    The Court underscored that Kyocera does not impose a temporal requirement, and it declined to infer one. It reasoned that an expert can acquire the necessary skill later and still reliably opine from the perspective of a person of ordinary skill at the relevant time. The Court further noted that Planmeca had not filed a Daubert motion or otherwise timely challenged Dr. Kia’s qualifications at trial, weakening its post-verdict objections.

    Substantial Evidence of Infringement

    Planmeca also challenged the jury’s infringement verdict on several claim limitations, including densitometry, tomographic modeling, and comparing digital models. The Federal Circuit upheld the verdict, finding substantial evidence for each element:

    • Densitometry: The Court found that the accused systems’ calculation of Hounsfield Units (HU) constituted “quantitatively calculated bone density” under the court’s claim construction.
    • Tomographic Model: Dr. Kia’s testimony supported that the systems merged data from multiple tomographic scans, satisfying the claim limitation.
    • Comparing Models: The Court rejected Planmeca’s contention that a human, not the computer, must perform the comparison. It held that presenting models in a way that enables comparison—such as side-by-side alignment—was sufficient.

    Obviousness: Competing Expert Testimony

    As for validity, Planmeca contended that the asserted claims were obvious over a combination of prior art references, including Guenther, Mazess, Fontevraud, and DIMAXIS. However, the Federal Circuit held that substantial evidence supported the jury’s nonobviousness verdict. Dr. Kia testified that combining tomosynthesis (Guenther) with densitometric techniques (Mazess and Fontevraud) would not have been obvious due to the incompatibility between these imaging methods. The Court declined to reweigh the expert testimony or second-guess the jury’s credibility determinations.

    Takeaways

    • No Time-of-Invention Requirement for Expert Qualification: This decision reaffirms that an expert need only possess the requisite skill in the art—when they acquired it is immaterial for purposes of testifying from the perspective of a POSITA.
    • Preservation Matters: The failure to timely challenge expert qualifications under Daubert or through trial objections may limit avenues for appeal.
    • Substantial Evidence Standard Remains Robust: The Federal Circuit continues to defer to jury verdicts where the record reflects a reasonable basis for the findings, even in the face of competing expert testimony.

    This decision serves as a reminder to focus early on expert qualification issues and underscores the importance of building a complete record—both for and against infringement and validity—at trial.

    By Charles Gideon Korrell